World News
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
Business & Economy
These are the stocks posting the largest moves midday.
Technology
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
Technology
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Business & Economy
These are the stocks posting the largest moves in the premarket.